These findings were not confirmed in our study: when applying the delta SUV response criterion, 11 MYC + DLBCL patients were positive at I-PET (13.8%), which was not significantly higher than the proportion of I-PET positive patients in MYC- DLBCL patients (9.6%, n = 12). This evidence concerns the gene MYC and diffuse large B-cell lymphoma.